PRVA
Privia Health Group, Inc.
PRVA's fundamentals are strong and it looks cheap: trading at 88x earnings, below its usual 151x. Analysts expect strong earnings growth, though they disagree widely on how much.
PRVA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Healthy |
PRVA's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PRVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 54x | $23.67 | — |
| Current | 88x | $23.67 | — |
| Cheap | 90x | $24.32 | +2.7% |
| Fair | 150x | $40.60 | +72% |
| Expensive | 207x | $55.80 | +136% |
Historical ranges are pointers, not guarantees.
PRVA's PE is in its cheap range at 88x. If earnings grow as analysts expect, today's price would be 54x next year's earnings.
PRVA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for PRVA, with profitability improving. However, they disagree widely on these estimates.
PRVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.44 | +61% |
| Q3 2026 | $0.27 | +108% |
| Q2 2026 | $0.22 | +100% |
| Q1 2026 | $0.17 | +42% |
| Q4 2025 | $0.18 | +64% |
| Q3 2025 | $0.13 | +30% |
| Q2 2025 | $0.11 | -8.3% |
| Q1 2025 | $0.12 | -20% |
| Q4 2024 | $0.11 | -42% |
PRVA earned $0.27 per share over the past year, up 108% from the year before.
PRVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $657M | +13% |
| Q2 2026 | $632.6M | +21% |
| Q1 2026 | $603.8M | +26% |
| Q4 2025 | $541.2M | +17% |
| Q3 2025 | $580.4M | +33% |
| Q2 2025 | $521.2M | +23% |
| Q1 2025 | $480.1M | +16% |
| Q4 2024 | $460.9M | +4.6% |
PRVA's revenue has grown year over year every quarter since early 2021: $657M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.1% | +0.6 points |
| Q2 2026 | 1.9% | +1.2 points |
| Q1 2026 | 1.2% | +0.1 points |
| Q4 2025 | 2.1% | +0.9 points |
| Q3 2025 | 2.5% | +1.1 points |
| Q2 2025 | 0.6% | -0.6 points |
| Q1 2025 | 1.1% | +0.9 points |
| Q4 2024 | 1.1% | +0.8 points |
PRVA's operating margin was 3.1% last quarter, up 0.6 points from the same quarter a year ago.
PRVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.9M | -44% |
| Q2 2026 | $1.1M | -86% |
| Q1 2026 | -$49.5M | -$25.4M |
| Q4 2025 | $127.5M | +70% |
| Q3 2025 | $52M | +57% |
| Q2 2025 | $8M | -77% |
| Q1 2025 | -$24.1M | +$9.1M |
| Q4 2024 | $74.8M | +17% |
PRVA generated $108M in free cash flow over the past year, down 2.4% from the year before.
PRVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +883K shares |
| 1 year | +3.1% | +3.9M shares |
| 3 years | +6.2% | +7.8M shares |
| 5 years | +25% | +26.8M shares |
| Available history | +29% | +29.9M shares |
PRVA has 133M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PRVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -7.0x | Net Cash |
| Q2 2026 | -7.2x | Net Cash |
| Q1 2026 | -8.8x | Net Cash |
| Q4 2025 | -10.9x | Net Cash |
| Q3 2025 | -11.8x | Net Cash |
| Q2 2025 | -14.1x | Net Cash |
| Q1 2025 | -16.3x | Net Cash |
| Q4 2024 | -20.3x | Net Cash |
PRVA has more cash than debt.
PRVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.1 | Neutral |
| Stochastic | 71.7 | Neutral |
PRVA's weekly RSI is 55 (neutral) and its Stochastic is 72 (neutral).
PRVA PE vs Healthcare Sector
| Metric | PRVA | Sector median | Relative |
|---|---|---|---|
| PE | 88x | 26x | 239% above |
| PE % | 15 | 36 | 21 pts below |
PRVA is trading at 88x earnings, a 239% premium to the Healthcare sector's median of 26x.
PRVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.9 | 8% above |
| 20 week MA | $22.7 | 4.4% above |
| 50 week MA | $22.9 | 3.4% above |
| 100 week MA | $22.9 | 3.6% above |
| 200 week MA | $22.6 | 4.9% above |
PRVA is in an uptrend: it's above all five of its weekly moving averages, and 4.9% above its 200-week average.
PRVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $36.3 | $26.2 | -28% |
| 2022 | $26.2 | $23.4 | -11% |
| 2023 | $23.4 | $23.0 | -1.6% |
| 2024 | $23.0 | $19.9 | -14% |
| 2025 | $19.9 | $24.1 | +22% |
| 2026 YTD | $24.1 | $23.7 | -1.9% |
PRVA has finished lower in four of the last five years. It's down 1.9% so far in 2026.